Results 191 to 200 of about 138,081 (263)

Plasma metabolites after 10-weeks of glucose vs fructose-sweetened beverages in subjects with overweight/obesity. [PDF]

J Endocr Soc
Guirette M, Haslam DE, Ma J, Havel PJ, Stanhope KL, Ilkayeva O, Newgard CB, McKeown NM, Herman MA.   +8 more
europepmc   +1 more source

Seasonal Dynamics of Community and Function of Gut Microbiome in Taihangshan Macaque (Macaca mulatta tcheliensis): Inferred From Metagenomic Data

Integrative Zoology, EarlyView.
A total of 435 non‐redundant metagenome‐assembled genomes (MAGs) were obtained from fecal samples of Taihangshan macaque across all four seasons. The alpha diversity of the gut microbiome in spring and winter was significantly higher than in summer and autumn. Furthermore, marked differences were detected in functional pathways and carbohydrate enzymes
Yanyan Zhou, Qi Shao, Chunbo Liu, Jundong Tian, Xiaowen Guan, Xi Zhang, Jiqi Lu   +6 more
wiley   +1 more source

3-hydroxyisobutyryl-CoA hydrolase deficiency: a case description. [PDF]

Quant Imaging Med Surg
Jiang L, Wu M, Qin W, Qin L, Cheng G, Qin H, Wei J, Liao Z, Wei X, Yang L, Wei H, Qin X.   +11 more
europepmc   +1 more source

Polypropylene Nanoplastic Exposure to Respiratory Epithelial Barrier‐On‐Chip and Interfacial Interactions With Human Serum Albumin

Allergy, EarlyView.
Exposure to 305 nm PP NPs significantly disrupts the airway barrier‐on‐chip, reducing TEER, suppressing ZO‐1/ACE2 expression, and triggering ROS‐mediated apoptosis. In biological media, PP NPs exhibit a biphasic adsorption pattern, leading to the formation of a protein corona that increases their size to 364 nm.
Omur Sert, Eyup Bilgi, Reyhan Coban, Pelin Saglam‐Metiner, Basar Dogan, Zeynep Imir‐Tekneci, Suleyman Selim Cinaroglu, Ozlem Goksel, Ceyda Oksel Karakus, Ozlem Yesil‐Celiktas   +9 more
wiley   +1 more source

Two new factors modulating <i>Bacillus subtilis</i> spore resistance and germination. [PDF]

mSphere
Bannon WJ, Padilla D, Suryadevara D, Ye F, Korza G, Wicander J, Setlow P.   +6 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

An exploratory investigation of β-aminoisobutyric acid as a biomarker: possible relationships between urinary BAIBA and lifestyle habits. [PDF]

Biochem Biophys Rep
Suzuki M, Shimba Y, Sakai A, Kobayashi A, Shibayama S, Takahashi C, Shibata M, Kiyosawa T, Obana Y, Yamada Y, Hosaka T.   +10 more
europepmc   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr‐Mutant Lung Cancer Mouse Model

Cancer Science, EarlyView.
Using an immunocompetent mouse model of Egfr Ex19del‐driven lung cancer, we found that osimertinib‐resistant tumors acquired Egfr V804F, the murine counterpart of human EGFR V802F. Afatinib, but not osimertinib, suppressed phosphorylation of EGFR and overcame V804F‐mediated resistance, providing a preclinical rationale for biomarker‐guided therapy ...
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, Iwao Shimomura, Sachi Okawa, Shunta Mori, Tadahiro Kuribayashi, Jun Nishimura, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya, Go Makimoto, Hisao Higo, Kammei Rai, Eiki Ichihara, Shuta Tomida, Katsuyuki Hotta, Yosuke Togashi, Yoshinobu Maeda, Katsuyuki Kiura, Ryohei Katayama, Kadoaki Ohashi   +22 more
wiley   +1 more source

Multistep metabolic engineered <i>Klebsiella oxytoca</i> for efficient l-leucine production. [PDF]

Synth Syst Biotechnol
Sun W, Yang Q, Wang S, Gong L, Zhou Z, Liu M, Tan X, Kang Q, Meng W, Liu Y, Kang Z, Xu P, Ma C, Gao C, Lü C.   +14 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source